Approaches to comparative effectiveness research in multimorbid populations

Medical Care

Volumn 52, Issue 3 SUPPL. 2, 2014, Pages

  Maciejewski, Matthew L ^a,b   Bayliss, Elizabeth A ^c,d  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Kaiser Permanente Colorado   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Chronic conditions; Comparative effectiveness research; Complexity; Experiment; Multimorbidity; Observational; Outcomes; Quasi experiment; Statistics; Treatment effect

Indexed keywords

CHRONIC DISEASE; COMPARATIVE EFFECTIVENESS RESEARCH; DELIVERY OF HEALTH CARE; DELIVERY OF HEALTH CARE, INTEGRATED; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; PRIMARY HEALTH CARE; UNITED STATES;

EID: 84894461681     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000060     Document Type: Review

References (61)

1. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: Implications for pay for performance. JAMA. 2005;294:716-724. (Pubitemid 41159291)
2. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition - multimorbidity. JAMA. 2012;307: 2493-2494.
3. Tinetti ME, Bogardus ST Jr, Agostini JV. Potential pitfalls of diseasespecific guidelines for patients with multiple conditions. N Engl J Med. 2004;351:2870-2874.
4. American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. Patient-centered care for older adults with multiple chronic conditions: A stepwise approach from the American Geriatrics Society. J Am Geriatr Soc. 2012;60:1957-1968.
5. Boyd CM, Fortin M. Future of multimorbidity research: How should understanding of multimorbidity inform health system design? Public Health Rev. 2011;32:451-474.
6. Tinetti ME, Studenski SA. Comparative effectiveness research and patients with multiple chronic conditions. N Engl J Med. 2011;364: 2478-2481.
7. Parekh AK, Goodman RA, Gordon C, et al. Managing multiple chronic conditions: A strategic framework for improving health outcomes and quality of life. Public Health Rep. 2011;126:460-471.
8. Sox HC, Greenfield S. Comparative effectiveness research: A report from the Institute of Medicine. Ann Intern Med. 2009;151:203-205.
9. Fortin M, Dionne J, Pinho G, et al. Randomized controlled trials: Do they have external validity for patients with multiple comorbidities? Ann Fam Med. 2006;4:104-108.
10. Smith SM, Soubhi H, Fortin M, et al. Managing patients with multimorbidity: Systematic review of interventions in primary care and community settings. BMJ. 2012;345:e5205.
11. Brookhart MA, Sturmer T, Glynn RJ, et al. Confounding control in healthcare database research: Challenges and potential approaches. Med Care. 2010;48(suppl):S114-S120.
12. Maciejewski ML, Curtis LH, Dowd BE. Study design elements for rigorous quasi-experimental comparative effectiveness research. J Comp Effect Res. 2013;2:159-173.
13. Berger ML, Dreyer N, Anderson F, et al. Prospective observational studies to assess comparative effectiveness: The ISPOR good research practices task force report. Value Health. 2012;15:217-230.
14. Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative effectiveness research: Approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report - Part II. Value Health. 2009;12:1053-1061.
15. Dreyer NA, Schneeweiss S, McNeil BJ, et al. GRACE principles: Recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care. 2010;16:467-471.
16. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann Intern Med. 2007;147:573-577. (Pubitemid 351664504)
17. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: Increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632. (Pubitemid 37430387)
18. Larson EB. N-of-1 clinical trials. A technique for improving medical therapeutics. West J Med. 1990;152:52-56. (Pubitemid 20043006)
19. Steinman MA, Lee SJ, John Boscardin W, et al. Patterns of multimorbidity in elderly veterans. J Am Geriatr Soc. 2012;60:1872-1880.
20. Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286:821-830. (Pubitemid 33015576)
21. Safford MM, Allison JJ, Kiefe CI. Patient complexity: More than comorbidity. The vector model of complexity. J Gen Intern Med. 2007; 22(suppl 3):382-390. (Pubitemid 350172453)
22. Shippee ND, Shah ND, May CR, et al. Cumulative complexity: A functional, patient-centered model of patient complexity can improve research and practice. J Clin Epidemiol. 2012;65:1041-1051.
23. Schneeweiss S, Patrick AR, Sturmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(suppl 2):S131-S142.
24. Foley FW, LaRocca NG, Sanders AS, et al. Rehabilitation of intimacy and sexual dysfunction in couples with multiple sclerosis. Mult Scler. 2001;7:417-421. (Pubitemid 33138354)
25. Maciejewski ML, Farley JF, Parker J, et al. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29:2002-2008.
26. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139. (Pubitemid 41587600)
27. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27. (Pubitemid 128456396)
28. Chaudhry S, Jin L, Meltzer D. Use of a self-report-generated Charlson Comorbidity Index for predicting mortality. Med Care. 2005;43: 607-615. (Pubitemid 40847298)
29. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
30. Bayliss EA, Ellis JL, Steiner JF. Seniors' self-reported multimorbidity captured biopsychosocial factors not incorporated into two other databased morbidity measures. J Clin Epidemiol. 2009;62:550-557. e551.
31. Sangha O, Stucki G, Liang MH, et al. The Self-Administered Comorbidity Questionnaire: A new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49:156-163. (Pubitemid 36418272)
32. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622-626.
33. Hudon C, Fortin M, Vanasse A. Cumulative Illness Rating Scale was a reliable and valid index in a family practice context. J Clin Epidemiol. 2005;58:603-608. (Pubitemid 40692726)
34. Fortin M, Hudon C, Dubois MF, et al. Comparative assessment of three different indices of multimorbidity for studies on health-related quality of life. Health Qual Life Outcomes. 2005;3:74.
35. Bayliss EA, Ellis JL, Shoup JA, et al. Association of patient-centered outcomes with patient-reported and ICD-9-based morbidity measures. Ann Fam Med. 2012;10:126-133.
36. Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006;22:281-285.
37. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269-2276. (Pubitemid 35332510)
38. Bottle A, Gnani S, Saxena S, et al. Association between quality of primary care and hospitalization for coronary heart disease in England: National cross-sectional study. J Gen Intern Med. 2008;23:135-141. (Pubitemid 351208241)
39. Wu AW, Snyder C, Clancy CM, et al. Adding the patient perspective to comparative effectiveness research. Health Aff (Millwood). 2010;29: 1863-1871.
40. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82:661-687. (Pubitemid 40143102)
41. Farley JF, Lindquist J, Wansink D, et al. Medication adherence changes associated with value based insurance design. Am J Manag Care. 2012; 18:265-274.
42. Basu A. Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. J Health Econ. 2011;30:549-559.
43. Greenfield S, Kravitz R, Duan N, et al. Heterogeneity of treatment effects: Implications for guidelines, payment, and quality assessment. Am J Med. 2007;120(suppl 1):S3-S9. (Pubitemid 46497038)
44. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. JAMA. 2007;298:1209-1212. (Pubitemid 47403108)
45. Lagakos SW. The challenge of subgroup analyses - reporting without distorting. N Engl J Med. 2006;354:1667-1669.
46. Kent DM, Rothwell PM, Ioannidis JP, et al. Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal. Trials. 2010;11:85.
47. Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: A cohort study. Ann Intern Med. 2009;151:854-860.
48. Wang V, Liu CF, Bryson CL, et al. Does medication adherence following a copayment increase differ by disease burden? Health Serv Res. 2011;46(6 pt 1):1963-1985.
49. Kaplan SH, Billimek J, Sorkin DH, et al. Who can respond to treatment? Identifying patient characteristics related to heterogeneity of treatment effects. Med Care. 2010;48(suppl):S9-S16.
50. Rothwell PM, Warlow CP. Prediction of benefit from carotid endarterectomy in individual patients: A risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet. 1999;353: 2105-2110. (Pubitemid 29278479)
51. Kent DM, Hayward RA, Griffith JL, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med. 2002;113:104-111. (Pubitemid 34804746)
52. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke. 2003;34: 464-467. (Pubitemid 36206349)
53. Hayward RA, Krumholz HM, Zulman DM, et al. Optimizing statin treatment for primary prevention of coronary artery disease. Ann Intern Med. 2010;152:69-77.
54. Kent DM, Shah ND. Risk models and patient-centered evidence: Should physicians expect one right answer? JAMA. 2012;307:1585-1586.
55. Kiernan M, Kraemer HC, Winkleby MA, et al. Do logistic regression and signal detection identify different subgroups at risk? Implications for the design of tailored interventions. Psychol Methods. 2001;6:35-48. (Pubitemid 33610294)
56. Newcomer SR, Steiner JF, Bayliss EA. Identifying subgroups of complex patients with cluster analysis. Am J Manag Care. 2011; 17:e324-e332.
57. Bayliss EA, Blatchford PJ, Newcomer SR, et al. The effect of incident cancer, depression and pulmonary disease exacerbations on type 2 diabetes control. J Gen Intern Med. 2011;26:575-581.
58. Jo B, Wang CP, Ialongo NS. Using latent outcome trajectory classes in causal inference. Stat Interface. 2009;2:403-412.
59. Muthen B, Brown HC. Estimating drug effects in the presence of placebo response: Causal inference using growth mixture modeling. Stat Med. 2009;28:3363-3385.
60. Neelon B, O'Malley AJ, Normand SL. A Bayesian two-part latent class model for longitudinal medical expenditure data: Assessing the impact of mental health and substance abuse parity. Biometrics. 2011;67:280-289.
61. National Quality Forum. Multiple chronic conditions measurement framework. Available at: Http://www.qualityforum.org/Publications/2012/05/MCC- Measurement-Framework-Final-Report.aspx. Accessed January 18, 2013.